Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm

Bettina Wabbels, Wolfgang H Jost, Peter Roggenkämper, Bettina Wabbels, Wolfgang H Jost, Peter Roggenkämper

Abstract

Blepharospasm is a focal dystonia in which the extraocular muscles contract repetitively, leading to excessive blinking and forced eyelid closure. Botulinum toxin type A (BoNTA) is the primary symptomatic treatment for blepharospasm and its effects have been evaluated using numerous rating scales. The main scales in use today were initially used to determine whether BoNTA treatment was superior to placebo, and most controlled trials have confirmed this. More recently, these scales have been used to determine whether there are efficacy differences between different BoNTs in blepharospasm. However, although the scales used in these trials are able to differentiate the effects of BoNT from placebo, they may not be sensitive enough to differentiate between BoNTs. Most of the scales include only four possible points for each item, which would necessitate a 25% greater improvement in one group than the other to detect any differences. Current scales are also relatively insensitive to patients with mild disability who may experience mainly psychosocial problems related to their blepharospasm. Clinical trials comparing BoNTs that include substantial numbers of mildly affected patients may be unlikely to find differences because the scales do not adequately measure mild symptoms. Additional challenges with evaluating blepharospasm include the lack of precision and objectivity of current measures, symptom variability, the need to evaluate aspects of the disorder that are most important to patients, and the different types of blepharospasm. Although no single scale may be able to capture all relevant aspects of blepharospasm, more sensitive and patient-centered scales are needed.

Figures

Fig. 1
Fig. 1
Jankovic Rating Scale (Jankovic and Orman 1987)
Fig. 2
Fig. 2
Blepharospasm Disability Index (Roggenkämper et al. 2006); scale originally described in Goertelmeyer et al.

References

    1. Aramideh M, Ongerboer de Visser BW, Devriese PP, Bour LJ, Speelman JD. Electromyographic features of levator palpebrae superioris and orbicularis oculi muscles in blepharospasm. Brain. 1994;117(Pt 1):27–38. doi: 10.1093/brain/117.1.27.
    1. Boyle MH, McGwin G, Jr, Flanagan CE, Vicinanzo MG, Long JA. High versus low concentration botulinum toxin A for benign essential blepharospasm: does dilution make a difference? Ophthal Plast Reconstr Surg. 2009;25:81–84. doi: 10.1097/IOP.0b013e31819946c4.
    1. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee CH, Jenkins S, Turkel C. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347:395–400. doi: 10.1056/NEJMoa011892.
    1. Brin M, Blitzer A, Herman S, Steward C. Oromandibular dystonia: treatment of 96 cases with botulinum A. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. pp. 429–435.
    1. Brin MF, Jankovic J, Comella C, Blitzer A, Tsui JKC, Pullman SL. Treatment of dystonia using botulinum toxin. In: Kurlan R, editor. Treatment of movement disorders. New York: Lippincott Company; 1995. pp. 183–246.
    1. Casse G, Adenis JP, Sauvage JP, Robert PY. Videonystagmography as a tool to assess blepharospasm before and after botulinum toxin injection. Graefes Arch Clin Exp Ophthalmol. 2008;246:1307–1314. doi: 10.1007/s00417-008-0877-5.
    1. Casse G, Adenis JP, Sauvage JP, Robert PY. Videonystagmography to assess eyelid dynamic disorders. Orbit. 2009;28:20–24. doi: 10.1080/01676830802541004.
    1. Cohen DA, Savino PJ, Stern MB, Hurtig HI. Botulinum injection therapy for blepharospasm: a review and report of 75 patients. Clin Neuropharmacol. 1986;9:415–429. doi: 10.1097/00002826-198610000-00002.
    1. Elston JS. The management of blepharospasm and hemifacial spasm. J Neurol. 1992;239:5–8. doi: 10.1007/BF00839203.
    1. Elston JS, Russell RW. Effect of treatment with botulinum toxin on neurogenic blepharospasm. Br Med J (Clin Res Ed) 1985;290:1857–1859. doi: 10.1136/bmj.290.6485.1857.
    1. Fahn S. Rating scales for blepharopsasm. In: Bosniak SL, editor. Blepharopsasm, advanced ophthalmology plastic reconstructive surgery. New York: Pergamom Press; 1985. pp. 97–101.
    1. Fahn S, List T, Moskowitz C, Brin M, Bressman S, Burke RE, Scott A. Double-blind controlled study of botulinum toxin for blepharospasm. Neurology. 1985;35((Suppl 1)):271–272.
    1. Frueh BR, Nelson CC, Kapustiak JF, Musch DC. The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment. Am J Ophthalmol. 1988;106:45–47. doi: 10.1016/0002-9394(88)90610-1.
    1. Girlanda P, Quartarone A, Sinicropi S, Nicolosi C, Messina C. Unilateral injection of botulinum toxin in blepharospasm: single fiber electromyography and blink reflex study. Mov Disord. 1996;11:27–31. doi: 10.1002/mds.870110107.
    1. Goertelmeyer S, Brinkmann G, Comes A, Delcker A. The Blepharospasm Disability Index (BSDI) for the assessment of functional health in focal dystonia. Clin Neurophysiol. 2002;113:S77–S78.
    1. Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry. 1988;51:767–772. doi: 10.1136/jnnp.51.6.767.
    1. Hallett M. Blepharospasm: recent advances. Neurology. 2002;59:1306–1312.
    1. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987;37:616–623.
    1. Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009;24:407–413. doi: 10.1002/mds.22368.
    1. Lindeboom R, De Haan R, Aramideh M, Speelman JD. The blepharospasm disability scale: an instrument for the assessment of functional health in blepharospasm. Mov Disord. 1995;10:444–449. doi: 10.1002/mds.870100407.
    1. Mauriello JA, Jr, Dhillon S, Leone T, Pakeman B, Mostafavi R, Yepez MC. Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years. Br J Ophthalmol. 1996;80:1073–1076. doi: 10.1136/bjo.80.12.1073.
    1. Mezaki T, Kaji R, Brin MF, Hirota-Katayama M, Kubori T, Shimizu T, Kimura J. Combined use of type A and F botulinum toxins for blepharospasm: a double-blind controlled trial. Mov Disord. 1999;14:1017–1020. doi: 10.1002/1531-8257(199911)14:6<1017::AID-MDS1018>;2-3.
    1. Müller J, Wissel J, Kemmler G, Voller B, Bodner T, Schneider A, Wenning GK, Poewe W. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry. 2004;75:749–753. doi: 10.1136/jnnp.2003.013441.
    1. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ. 2001;323:596–599. doi: 10.1136/bmj.323.7313.596.
    1. Nussgens Z, Roggenkamper P. Long-term treatment of blepharospasm with botulinum toxin type A. Ger J Ophthalmol. 1995;4:363–367.
    1. Nussgens Z, Roggenkämper P. Comparison of two botulinum toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997;235:197–199. doi: 10.1007/BF00941758.
    1. Price J, Farish S, Taylor H, O’Day J. Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. Ophthalmology. 1997;104:865–868.
    1. Quagliato EM, Carelli EF, Viana MA. Prospective, randomized, double-blind study, comparing botulinum toxins type A Botox and Prosigne for blepharospasm and hemifacial spasm treatment. Clin Neuropharmacol. 2010;33:27–31.
    1. Rahman R, Berry-Brincat A, Thaller VT. A new grading system for assessing orbicularis muscle function. Eye. 2003;17:610–612. doi: 10.1038/sj.eye.6700444.
    1. Rieder CR, Schestatsky P, Socal MP, Monte TL, Fricke D, Costa J, Picon PD. A double-blind, randomized, crossover study of Prosigne versus Botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol. 2007;30:39–42. doi: 10.1097/01.WNF.0000236771.77021.3C.
    1. Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303–312. doi: 10.1007/s00702-005-0323-3.
    1. Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP, Bastos-Lima A, Martins R, Castro-Caldas A. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1. Mov Disord. 1997;12:1013–1018. doi: 10.1002/mds.870120627.
    1. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985;103:347–350.
    1. Simpson DM, Alexander DN, O’Brien CF, Tagliati M, Aswad AS, Leon JM, Gibson J, Mordaunt JM, Monaghan EP. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996;46:1306–1310.
    1. Truong D, Comella C, Fernandez HH, Ondo WG. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008;14:407–414. doi: 10.1016/j.parkreldis.2007.11.003.
    1. Tsoy EA, Buckley EG, Dutton JJ. Treatment of blepharospasm with botulinum toxin. Am J Ophthalmol. 1985;99:176–179.
    1. Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenkämper P (2010) Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm. [Epub ahead of print] PMID:21161715
    1. Wissel J, Muller J, Dressnandt J, Heinen F, Naumann M, Topka H, Poewe W. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manag. 2000;20:44–49. doi: 10.1016/S0885-3924(00)00146-9.
    1. Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009;23:137–141. doi: 10.3341/kjo.2009.23.3.137.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe